curacle co.,ltd. (KOSDAQ:365270)

Market Cap	256.21B +199.8%
Revenue (ttm)	1.14B -35.7%
Net Income	-17.50B
EPS	-1,217.16
Shares Out	21.16M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	698,521
Average Volume	825,056
Open	12,000
Previous Close	12,420
Day's Range	11,140 - 12,560
52-Week Range	3,600 - 13,150
Beta	2.17
RSI	66.49
Earnings Date	n/a

About curacle co.,ltd.

curacle co.,ltd., a bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging. The company’s products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema; CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition of TGF- β/Smad signaling; MT-101, a fully humanized Tie2 agonist antibody for the treatment of renal diseases; and MT-103, a bispecific antibody combi...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 365270

Financial Performance

In 2024, curacle co.,ltd.'s revenue was 1.63 billion, a decrease of -84.14% compared to the previous year's 10.29 billion. Losses were -14.89 billion, 28.5% more than in 2023.